LivaNova PLC (LIVN) Coverage Initiated by Analysts at Jefferies Group LLC
Equities research analysts at Jefferies Group LLC assumed coverage on shares of LivaNova PLC (NASDAQ:LIVN) in a note issued to investors on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $76.00 price target on the stock. Jefferies Group LLC’s price objective points to a potential upside of 15.10% from the company’s previous close.
Other equities research analysts have also recently issued reports about the stock. Berenberg Bank reaffirmed a “buy” rating and issued a $70.00 price objective on shares of LivaNova PLC in a research report on Friday, August 11th. BidaskClub cut shares of LivaNova PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. WBB Securities cut shares of LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 price objective on the stock. in a research report on Tuesday, August 15th. Finally, Needham & Company LLC assumed coverage on shares of LivaNova PLC in a research report on Wednesday, August 23rd. They issued a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $62.50.
Shares of LivaNova PLC (NASDAQ:LIVN) traded up 4.48% during mid-day trading on Friday, hitting $66.03. The company had a trading volume of 617,733 shares. The company has a market capitalization of $3.22 billion, a P/E ratio of 117.91 and a beta of 0.58. The firm’s 50-day moving average price is $61.71 and its 200 day moving average price is $56.91. LivaNova PLC has a one year low of $40.83 and a one year high of $66.30.
LivaNova PLC (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, August 9th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.82 by $0.19. The business had revenue of $321.40 million for the quarter, compared to analysts’ expectations of $315.75 million. LivaNova PLC had a net margin of 2.26% and a return on equity of 9.08%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. Analysts predict that LivaNova PLC will post $3.22 earnings per share for the current fiscal year.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $61.55, for a total value of $61,550.00. Following the sale, the director now directly owns 56,437 shares of the company’s stock, valued at approximately $3,473,697.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 3,000 shares of company stock worth $183,110 over the last ninety days. 0.28% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the business. Icon Advisers Inc. Co. bought a new stake in LivaNova PLC during the 1st quarter worth about $333,000. Airain ltd bought a new stake in LivaNova PLC during the 2nd quarter worth about $1,449,000. Bank of New York Mellon Corp lifted its position in LivaNova PLC by 5.1% during the 1st quarter. Bank of New York Mellon Corp now owns 374,488 shares of the company’s stock worth $18,353,000 after buying an additional 18,042 shares in the last quarter. Waverton Investment Management Ltd lifted its position in LivaNova PLC by 866.3% during the 2nd quarter. Waverton Investment Management Ltd now owns 111,220 shares of the company’s stock worth $6,808,000 after buying an additional 99,710 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in LivaNova PLC by 10.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 123,251 shares of the company’s stock worth $6,041,000 after buying an additional 11,197 shares in the last quarter. 82.36% of the stock is currently owned by hedge funds and other institutional investors.
LivaNova PLC Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.